Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repaglinide vs Insulin in CF-Related Diabetes
NCT00662714Phase 3Completed
- Sponsor
- Mukoviszidose Institut
- Start
- Sep 2001
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of repaglinide in cystic fibrosis-related diabetes (CFRD) (2 arms), sponsored by Mukoviszidose Institut. Primary endpoint: Glycated Hemoglobin A1c at 2 years. Started Sep 2001; status: completed.
02
Drugs
repaglinide
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT00662714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662714.